PHOTOCURE ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.4 NOK | +1.84% |
|
+1.09% | -17.80% |
Presenter SpeechDaniel Schneider (Executives)All right. Welcome, everyone. I'm Dan Schneider, ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Companyâs activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
55.4
NOK
Average target price
86
NOK
Spread / Average Target
+55.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.80% | 136M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- PHO Stock
- News Photocure ASA
- Transcript : Photocure ASA, Q4 2022 Earnings Call, Feb 23, 2023
